BTIG Reiterates Buy Rating on Guardant Health with $190 Target
BTIG analyst Mark Massaro reiterated a buy rating on Guardant Health, setting a $190 price target, a 26.64% upside from the current price.
Key Points
- BTIG analyst Mark Massaro reiterated a buy rating on Guardant Health, Inc. (GH) with a target price of $190 as of July 1, 2026.
- BTIG's $190 price target implies 26.64% upside from Guardant Health, Inc.'s ($GH) current $150.03 share price.
- Shares of GH traded near $150.03 on Wednesday, with a market cap of approximately $19.89 billion and a beta of 1.619.
- Guardant Health has seen institutional interest, with BlackRock and Vanguard among those adding to their positions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG analyst Mark Massaro has reiterated his buy rating on Guardant Health, Inc. (NasdaqGS: GH), maintaining a price target of $190. This reaffirmation came on July 1, 2026, as the stock traded near $150.03 on Wednesday.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On July 1, 2026, BTIG maintained its buy rating on Guardant Health with a $190 price target. Other analysts have also shown confidence in the stock. Guggenheim kept a buy rating with a $160 target on June 29, while Bernstein reinstated a buy rating with a $175 target on June 26. Barclays maintained a buy rating with a $150 target on June 24.
Guardant Health, Inc. Stock Down 7.1%
Shares of Guardant Health traded around $150.03 on Wednesday. The company has a market cap of approximately $19.89 billion. Its forward P/E ratio isn't meaningful as the company is not currently profitable. The stock's beta is 1.619, indicating it's more volatile than the market. Over the past year, the stock has ranged between $40.35 and $153.95, with a 50-day moving average of $112.55 and a 200-day moving average of $96.31.
$GH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Guardant Health, Inc.
Co-Chief Executive Officer Amirali Talasaz was active in recent insider transactions. On June 29, 2026, he sold 143,028 shares at an average price of $151.54 under a planned trading program. Earlier, on June 26, he sold 116,972 shares at an average price of $150.79, also under a planned program.
Other Institutional Activity in Guardant Health
Institutional investors have been active in Guardant Health. BlackRock, Inc. increased its holdings by 236,045 shares, bringing its total to 11,553,759 shares, valued at about $1.07 billion. Price T Rowe Associates added 1,387,611 shares, now holding 7,023,689 shares worth approximately $648.78 million. Vanguard Portfolio Management LLC opened a new position with 5,837,992 shares valued at about $539.26 million. Invesco Ltd. reduced its stake by 369,465 shares, now holding 4,946,469 shares valued at around $456.91 million.
About Guardant Health
Guardant Health, Inc. is a precision oncology company based in Palo Alto, California. It provides blood and tissue tests, focusing on cancer detection and treatment guidance. Its offerings include the Guardant360 CDx test for tumor mutation profiling and the Guardant Reveal test for early cancer detection. Dr. Helmy Eltoukhy leads the company, which employs approximately 2,490 people.
Bottom Line
BTIG's reaffirmation of a buy rating on Guardant Health, along with a $190 target, reflects ongoing confidence in the company's prospects. Investors often watch such analyst updates closely, though it's important to remember that these reports are based on past data and expectations.
Get Guardant Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.